Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ann G. Carr is active.

Publication


Featured researches published by Ann G. Carr.


British Journal of Haematology | 2010

Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study.

Blanche P. Alter; Neelam Giri; Sharon A. Savage; June A. Peters; Jennifer T. Loud; Lisa Leathwood; Ann G. Carr; Mark H. Greene; Philip S. Rosenberg

Fanconi anaemia (FA), dyskeratosis congenita (DC), Diamond‐Blackfan anaemia (DBA), and Shwachman‐Diamond syndrome (SDS) comprise major inherited bone marrow failure syndromes (IBMFS). Adverse events include severe bone marrow failure (BMF), myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and solid tumours (ST). The natural history of FA is well characterised; hazard rates in the other syndromes have not yet been quantified. An open cohort was established at the National Cancer Institute (NCI) in 2002. Patients enrolled prior to December, 2007 were followed up to December, 2008. Diagnoses were confirmed with standard tests. Age‐associated risks of adverse events were calculated. Most patients in each syndrome survived to young adulthood. Patients with FA had earlier onset of cancers, need for stem cell transplant, and death; followed by DC; DBA and SDS were mildest. While FA and DC patients had markedly increased risks of cancer, AML and MDS, there were no cases of leukaemia in DBA or SDS patients. The NCI cohort provides the first direct quantitative comparison of timing and magnitude of cancer risk in the IBMFS. The findings demonstrate that both FA and DC are major cancer susceptibility syndromes. The IBMFS, historically considered paediatric disorders, have important management implications for physicians treating adult patients.


The Journal of Clinical Endocrinology and Metabolism | 2017

Quantification of thyroid cancer and multinodular goiter risk in the DICER1 syndrome: a family-based cohort study.

Nicholas E. Khan; Andrew J. Bauer; Kris Ann P. Schultz; Leslie Doros; Rosamma DeCastro; Alexander Ling; Maya Lodish; Laura A. Harney; Ron G. Kase; Ann G. Carr; Christopher T. Rossi; Amanda Field; Anne K. Harris; Gretchen M. Williams; Louis P. Dehner; Yoav Messinger; D. Ashley Hill; Douglas R. Stewart

Context: The risk of thyroid cancer and multinodular goiter (MNG) in DICER1 syndrome, a rare tumor-predisposition disorder, is unknown. Objective: To quantify the risk of thyroid cancer and MNG in individuals with DICER1 syndrome. Design: Family-based cohort study. Setting: National Institutes of Health (NIH) Clinical Center (CC). Participants: The National Cancer Institute DICER1 syndrome cohort included 145 individuals with a DICER1 germline mutation and 135 family controls from 48 families. Interventions: Each individual completed a detailed medical history questionnaire. A subset underwent a 3-day evaluation at the NIH CC. Main Outcome Measures: The cumulative incidence of MNG (or thyroidectomy) was quantified using the complement of the Kaplan-Meier product limit estimator. We compared the observed number of thyroid cancers in the NCI DICER1 cohort with matched data from the Surveillance, Epidemiology, and End Results (SEER) Program. We performed germline and somatic (thyroid cancer, MNG) DICER1 sequencing. Results: By the age of 40 years, the cumulative incidence of MNG or thyroidectomy was 75% in women and 17% in men with DICER1 syndrome compared with 8% of control women (P < 0.001) and 0% of control men (P = 0.0096). During 3937 person-years of observation, individuals with DICER1 syndrome had a 16-fold increased risk of thyroid cancer (95% confidence interval, 4.3 to 41; P < 0.05) compared with the SEER rates. Of 19 MNG nodules and 3 thyroid cancers, 16 (84%) and 3 (100%), respectively, harbored germline and somatic pathogenic DICER1 mutations. Conclusions: We propose a model of thyroid carcinogenesis in DICER1 syndrome. Early-onset, familial, or male MNG should prompt consideration of the presence of DICER1 syndrome.


Journal of Genetic Counseling | 2008

Testicular Cancer and Genetics Knowledge Among Familial Testicular Cancer Family Members

June A. Peters; Ellen Burke Beckjord; Deliya R. Banda Ryan; Ann G. Carr; Susan T. Vadaparampil; Jennifer T. Loud; Larissa M. Korde; Mark H. Greene

PurposeIt was our aim to determine baseline levels of testicular cancer and genetics knowledge among members of families with Familial Testicular Cancer (FTC).MethodsThis is a sub-study of an ongoing National Cancer Institute (NCI) multidisciplinary, etiologically-focused, cross-sectional study of FTC. We evaluated 258 male and female participants including testicular cancer (TC) survivors, blood relatives and spouses to assess factors associated with a Genetic Knowledge Scale (GKS) and Testicular Cancer Knowledge Scale (TCKS).ResultsKnowledge levels were generally low, with genetic knowledge lower than TC knowledge (p < 0.01). Men with a personal TC history scored highest on TC knowledge, while gender, age and education differentially influenced knowledge levels, particularly among unaffected relatives.ConclusionsPrior to identifying FTC susceptibility genes, we recommend tailoring FTC genetic education to the different informational needs of TC survivors, their spouses and relatives, in preparation for the day when clinical susceptibility testing may be available.


Genetics in Medicine | 2017

Macrocephaly associated with the DICER1 syndrome.

Nicholas E. Khan; Andrew J. Bauer; Leslie Doros; Kris Ann P. Schultz; Rosamma DeCastro; Laura A. Harney; Ron G. Kase; Ann G. Carr; Anne Harris; Gretchen M. Williams; Louis P. Dehner; Yoav Messinger; Douglas R. Stewart

Purpose:Germ-line mutations in DICER1 increase the risk of various tumors, including pleuropulmonary blastoma. Macrocephaly and symmetric overgrowth have been reported in some, but not all, patients with mosaic DICER1 RNase IIIb mutations. The prevalence of these features in individuals with constitutional germ-line DICER1 mutations is unknown.Methods:We analyzed prospectively collected auxology data from 67 DICER1 mutation carriers and 43 family controls. We assessed differences between groups using an exact test for proportions and generalized estimating equations for continuous dependent variables.Results:Twenty-eight DICER1 mutation carriers (42%) were macrocephalic, and none had an occipitofrontal circumference (OFC) below the third centile, which significantly differed from family controls, of whom five were macrocephalic (12%) and two had OFC below the third centile (5%) (P < 0.001). DICER1 mutation carriers were taller than familial controls after controlling for gender (P = 0.048), but similar proportions of both groups were above the 97th centile of population norms. Head circumference remained increased after adjusting for differences in height.Conclusion:For the first time, we establish macrocephaly as a common finding in the DICER1 syndrome. Like some other tumor-predisposition disorders, macrocephaly may be a useful, albeit a subtle, clinical clue to the DICER1 syndrome diagnosis.Genet Med 19 2, 244–248.


Clinical Cancer Research | 2018

DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies

Kris Ann P. Schultz; Gretchen M. Williams; Junne Kamihara; Douglas R. Stewart; Anne Harris; Andrew J. Bauer; Joyce Turner; Rachana Shah; Katherine A. Schneider; Kami Wolfe Schneider; Ann G. Carr; Laura A. Harney; Shari Baldinger; A. Lindsay Frazier; Daniel Orbach; Dominik T. Schneider; David Malkin; Louis P. Dehner; Yoav Messinger; D. Ashley Hill

Pathogenic germline DICER1 variants cause a hereditary cancer predisposition syndrome with a variety of manifestations. In addition to conferring increased cancer risks for pleuropulmonary blastoma (PPB) and ovarian sex cord–stromal tumors, particularly Sertoli–Leydig cell tumor, individuals with pathogenic germline DICER1 variants may also develop lung cysts, cystic nephroma, renal sarcoma and Wilms tumor, nodular hyperplasia of the thyroid, nasal chondromesenchymal hamartoma, ciliary body medulloepithelioma, genitourinary embryonal rhabdomyosarcoma, and brain tumors including pineoblastoma and pituitary blastoma. In May 2016, the International PPB Registry convened the inaugural International DICER1 Symposium to develop consensus testing and surveillance and treatment recommendations. Attendees from North America, Europe, and Russia provided expert representation from the disciplines of pediatric oncology, endocrinology, genetics, genetic counseling, radiology, pediatric surgery, pathology, and clinical research. Recommendations are provided for genetic testing; prenatal management; and surveillance for DICER1-associated pulmonary, renal, gynecologic, thyroid, ophthalmologic, otolaryngologic, and central nervous system tumors and gastrointestinal polyps. Risk for most DICER1-associated neoplasms is highest in early childhood and decreases in adulthood. Individual and caregiver education and judicious imaging-based surveillance are the primary recommended approaches. These testing and surveillance recommendations reflect a consensus of expert opinion and current literature. As DICER1 research expands, guidelines for screening and treatment will continue to be updated. Clin Cancer Res; 24(10); 2251–61. ©2018 AACR.


Pediatric Nephrology | 2018

Structural renal abnormalities in the DICER1 syndrome: a family-based cohort study

Nicholas E. Khan; Alexander Ling; Molly E. Raske; Laura A. Harney; Ann G. Carr; Amanda Field; Anne Harris; Gretchen M. Williams; Louis P. Dehner; Yoav Messinger; D. Ashley Hill; Kris Ann P. Schultz; Douglas R. Stewart

BackgroundThe DICER1 syndrome is a tumor-predisposition disorder caused by germline pathogenic variation in DICER1 and is associated with cystic nephroma and other renal neoplasms. Dicer1 mouse and rare human DICER1 syndrome case reports describe structural kidney and collecting system anomalies. We investigated renal function and the frequency of structural abnormalities of the kidney and collecting system in individuals with germline loss-of-function variants in DICER1.MethodsIn this family-based cohort study, prospectively ascertained germline DICER1-mutation carriers (DICER1-carriers) and unaffected family controls were evaluated at the National Institutes of Health Clinical Center with renal ultrasound and comprehensive laboratory testing. Two radiologists reviewed the imaging studies from all participants for structural abnormalities, cysts, and tumors.ResultsEighty-nine DICER1-carriers and 61 family controls were studied. Renal cysts were detected in 1/33 DICER1-carrier children without history of cystic nephroma. Similar proportions of adult DICER1-carriers (8/48; 17%) and controls (11/50; 22%) had ultrasound-detected renal cysts (P = 0.504). 8/89 (9%) DICER1-carriers harbored ultrasound-detected structural abnormalities of varying severity within the collecting system or kidney, nephrolithiasis, or nephrocalcinosis. None of the family controls (0/61) had similar findings on ultrasound (P = 0.02). No meaningful differences in renal laboratory values between DICER1-carriers and unaffected family controls were observed.ConclusionsOur report is the first to systematically characterize renal function and anatomy in a large prospective cohort of DICER1-carriers and DICER1-negative family controls. DICER1-carriers may be at increased risk of structural anomalies of the kidney or collecting system. The role for DICER1 in renal morphogenesis merits additional investigation.


Archive | 2014

DICER1-Related Disorders

Leslie Doros; Kris Ann P. Schultz; Douglas R. Stewart; Andrew J. Bauer; Gretchen M. Williams; Christopher T. Rossi; Ann G. Carr; Jiandong Yang; Louis P. Dehner; Yoav Messinger; D. Ashley Hill


Journal of Genetic Counseling | 2015

Genetic Information-Seeking Behaviors and Knowledge among Family Members and Patients with Inherited Bone Marrow Failure Syndromes

Jada G. Hamilton; Sadie P. Hutson; Amy E. Frohnmayer; Paul K. J. Han; June A. Peters; Ann G. Carr; Blanche P. Alter


Ophthalmology | 2018

DICER1 Syndrome: Characterization of the ocular phenotype in a family-based cohort study

Laryssa Huryn; Amy Turriff; Laura A. Harney; Ann G. Carr; Patricia Chévez-Barrios; Dan S. Gombos; Radha Ram; Robert B. Hufnagel; D. Ashley Hill; Wadih M. Zein; Kris Ann P. Schultz; Rachel J. Bishop; Douglas R. Stewart


Journal of Clinical Oncology | 2016

The role of nasal endoscopy screening for NCMH in the DICER1 syndrome.

Rosamma DeCastro; Shannon S. Givens; Jeffrey Kim; Lesley Doros; Laura A. Harney; Ann G. Carr; Anne Harris; Gretchen M. Williams; Louis P. Dehner; Yoav Messinger; Kris Ann P. Schultz; D. Ashley Hill; Douglas R. Stewart

Collaboration


Dive into the Ann G. Carr's collaboration.

Top Co-Authors

Avatar

Douglas R. Stewart

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Kris Ann P. Schultz

Children's Hospitals and Clinics of Minnesota

View shared research outputs
Top Co-Authors

Avatar

Gretchen M. Williams

Children's Hospitals and Clinics of Minnesota

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yoav Messinger

Children's Hospitals and Clinics of Minnesota

View shared research outputs
Top Co-Authors

Avatar

Andrew J. Bauer

Children's Hospital of Philadelphia

View shared research outputs
Top Co-Authors

Avatar

D. Ashley Hill

Children's National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Leslie Doros

Children's National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Anne Harris

Children's Hospitals and Clinics of Minnesota

View shared research outputs
Researchain Logo
Decentralizing Knowledge